GLOBAL TERBINAFINE MOMETASONE MARKET

INTRODUCTION

Treatments for itchy, puffy, and irritated skin involve mometasone. They can aid in treating psoriasis and various forms of eczema, such as atopic dermatitis and seborrheic dermatitis. Only on prescription are mometasone skin treatments available.

Treatment for fungal skin infections include eczema, psoriasis, ringworm, athlete's foot, jock itch, dermatitis, and tinea versicolor involves the use of MOMETASONE FUROATE+TERBINAFINE HYDROCHLORIDE.

A steroid drug is mometasone. The chemical messengers (prostaglandins) that cause the skin to become irritated, puffy, and red are prevented from being produced. By preventing fungus from developing their own protective layer, the antifungal terbinafine slows the growth of fungi. 

GLOBAL TERBINAFINE MOMETASONE MARKET SIZE AND FORECAST

The Global terbinafine mometasone market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.

NEW PRODUCT LAUNCH

ClaroTM, a new single-dose medication from Bayer, is available to treat canine otitis externa (florfenicol, terbinafine, mometasone furoate) Otic Solution offers vets a first-line treatment that is efficient and does not require pet owners to administer it at home. Inc.

Bayer HealthCare ClaroTM (15.0 mg/mL florfenicol, 13.3 mg/mL terbinafine, and 2.0 mg/mL mometasone furoate) Otic Solution, the first single-dose medication demonstrated to effectively treat susceptible strains of common infections prevalent in canine otitis externa, has been approved by Animal Health. This month, the product is anticipated to be sold only to veterinarians.

Otitis externa may be a frustrating condition for both canine patients and their owners and is the second most frequent reason dog owners bring their pet to the doctor.

The illness is an ear canal irritation that frequently has subsequent infections as a side effect. It often necessitates client administration of ear treatments at home and frequently results in pain, itching, a strong odour, and/or muted hearing in affected dogs.

The goal of Claro is to serve as a first-line treatment for otitis externa that meets the requirements of both dog owners and veterinarians. It is a single, veterinarian-administered treatment that is a clear liquid solution with a predetermined combination of antibacterial, antifungal, and anti-inflammatory chemicals.

The innovative single-dose treatment regimen removes the veterinarian's ambiguity regarding pet owner compliance and spares pet owners the difficulties of at-home administration and several treatment visits. Claro was created by Piedmont Animal Health in Greensboro, North Carolina, in collaboration with Bayer.

COMPANY PROFILE

• Bayer
• Vetoquinol
• Derma
• Sun pharmaceutical Industries Ltd
• MDPI

THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many terbinafine mometasone are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global terbinafine mometasone and key vendor selection criteria
3. Where is the terbinafine mometasone manufactured? What is the average margin per unit?
4. Market share of Global terbinafine mometasone market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global terbinafine mometasone in-house
6. key predictions for next 5 years in Global terbinafine mometasone market
7. Average B-2-B terbinafine mometasone market price in all segments
8. Latest trends in terbinafine mometasone market, by every market segment
9. The market size (both volume and value) of the terbinafine mometasone market in 2023-2030 and every year in between?
10. Production breakup of terbinafine mometasone market, by suppliers and their OEM relationship